Works matching IS 0008543X AND DT 2005 AND VI 103 AND IP 12

Results: 33
    1
    2
    3
    4
    5
    6
    7

    Capecitabine plus docetaxel combination therapyF. Hoffmann‐La Roche Ltd. supported the development of the model and the subsequent analyses. The sponsor had no role in the model design, cost‐effectiveness analysis, or interpretation of the results. All investigators had unlimited access to the model and data. No limitations on publication were imposed. The authors made the final decisions on all aspects of the current article.: Cost‐effectiveness in patients with anthracycline‐pretreated advanced breast carcinoma

    Published in:
    Cancer (0008543X), 2005, v. 103, n. 12, p. 2455
    By:
    • Shailendra Verma;
    • Dominique Maraninchi;
    • Joyce O'Shaughnessy;
    • Carol Jamieson;
    • Stephen Jones;
    • Miguel Martín;
    • Joseph McKendrick;
    • David Miles;
    • Chris Twelves;
    • John Hornberger
    Publication type:
    Article
    8

    Author reply.

    Published in:
    Cancer (0008543X), 2005, v. 103, n. 12, p. 2655
    By:
    • Yoshito Itoh;
    • Akiko Makiyama;
    • Takeshi Okanoue
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Similar long‐term results of breast‐conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breastPresented in part at the 45th annual meeting of the American Society for Therapeutic Radiology and Oncology, Salt Lake City, Utah, October 19–23, 2003.: The University of Pennsylvania experience

    Published in:
    Cancer (0008543X), 2005, v. 103, n. 12, p. 2447
    By:
    • Roberto J. Santiago;
    • Eleanor E. R. Harris;
    • Li Qin;
    • Wei‐Ting Hwang;
    • Lawrence J. Solin
    Publication type:
    Article
    25

    Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neckPresented, in part, at the 40th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 31–June 3, 2003; at the 41st Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 5–8, 2004; and at the 6th International Conference on Head and Neck Cancer, Washington, DC, August 7–11, 2004.The views expressed in the current article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.

    Published in:
    Cancer (0008543X), 2005, v. 103, n. 12, p. 2534
    By:
    • David L. Schwartz;
    • R. Bruce Montgomery;
    • Bevan Yueh;
    • Michael Donahue;
    • Yoshimi Anzai;
    • Raylene Canby;
    • Raelene Buelna;
    • Leslie Anderson;
    • Charles Boyd;
    • Janice Hutson;
    • Kathryn Keegan
    Publication type:
    Article
    26
    27
    28
    29

    Lymphatic and vascular embolizations are independent predictive variables of inguinal lymph node involvement in patients with squamous cell carcinoma of the penis: Gruppo Uro‐Oncologico del Nord Est (Northeast Uro‐Oncological Group) Penile Cancer Data Base data

    Published in:
    Cancer (0008543X), 2005, v. 103, n. 12, p. 2507
    By:
    • Vincenzo Ficarra;
    • Filiberto Zattoni;
    • Sergio Cosciani Cunico;
    • Tommaso Prayer Galetti;
    • Lucio Luciani;
    • Andrea Fandella;
    • Stefano Guazzieri;
    • Daniele Maruzzi;
    • Teodoro Sava;
    • Salvatore Siracusano;
    • Stefania Pilloni;
    • Andrea Tasca;
    • Guido Martignoni;
    • Marina Gardiman;
    • Regina Tardanico;
    • Tiziano Zambolin;
    • Antonio Cisternino;
    • Walter Artibani
    Publication type:
    Article
    30
    31
    32
    33